07:00 , Jun 3, 2013 |  BioCentury  |  Finance

Seeds to trees

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

Eladur transdur-bupivacaine: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 263 patients with chronic low back pain showed that 3 Eladur patches administered every 72 hours for 12 weeks missed the primary endpoint of significantly...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Company News

King, Pfizer deal

Pfizer will acquire King in a tender offer of $14.25 per share, or $3.6 billion in cash. The price is a 40% premium to King's close of $10.15 on Oct. 11, before the deal was...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Lux Biosciences management update

Lux Biosciences Inc. , Jersey City, N.J.   Business: Ophthalmic   Hired: Dean Mitchell as president and CEO, formerly president and CEO of Alpharma Inc. , which was acquired by King Pharmaceuticals Inc. in 2008;...
00:51 , Jul 2, 2010 |  BC Extra  |  Company News

Lux names Mitchell CEO

Ophthalmic company Lux Biosciences Inc. (Jersey City, N.J.) hired Dean Mitchell as president and CEO. Previously, Mitchell was president and CEO of Alpharma Inc. , which King Pharmaceuticals Inc. (NYSE:KG) acquired in 2008. He replaces...
07:00 , May 24, 2010 |  BioCentury  |  Finance

What knight?

By Stacy Lawrence Senior Writer...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Clinical News

Eladur transdur-bupivacaine: Phase IIb started

King began a double-blind, placebo-controlled Phase IIb trial to evaluate 3 Eladur patches administered every 72 hours for 12 weeks in 260 patients. King gained Eladur through its acquisition of Alpharma Inc. , which licensed...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

Embeda regulatory update

FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) issued a warning letter to King citing two video news releases promoting Embeda extended-release morphine/naltrexone. The agency said the videos are false or misleading by omitting...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

Embeda regulatory update

King said FDA approved Embeda to manage moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is an extended-release formulation of morphine, an opioid receptor...
00:02 , Aug 14, 2009 |  BC Extra  |  Company News

FDA approves King's Embeda

King Pharmaceuticals Inc. (NYSE:KG) said FDA approved Embeda to manage moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is an extended-release formulation of morphine,...